Shares of Natco Pharma jumped 4% in early morning trade following the release of its Q4 results. As of 9:30 AM, the shares were trading 2.64% higher at Rs 885.10.
The pharmaceutical major reported a consolidated net profit of ₹406 crore for the quarter ended March 31, 2025, reflecting a 5% increase compared to ₹386.3 crore in the same period last year. The revenue climbed 16% year-on-year to ₹1,287.3 crore from ₹1,110.3 crore in Q4 FY24.
The company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) stood at ₹548 crore, marking a 10.2% increase over the previous year. Despite this improvement, operating margins slightly compressed to 44.89% in the March quarter, down from 46.55% in the corresponding period last year.
Natco Pharma also achieved its highest-ever revenue and net profit for the full financial year 2024–25. The company reported a 16% rise in annual revenue to ₹4,784 crore, while net profit saw a substantial 36% surge to ₹1,883.4 crore.
Natco Pharma shares opened at ₹879.55, reaching a high of ₹919.50 and a low of ₹875.10 during the trading session. The stock is currently trading well below its 52-week high of ₹1,639.00, while remaining above the 52-week low of ₹726.80.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
